Why form and route matter
A concentration used in a laboratory assay does not establish a topical or systemic dose. Copper complex stability, delivery vehicle, exposure time, and endpoint all affect interpretation.
What a credible claim must identify
- The exact GHK-Cu form and assay.
- The route and delivery vehicle.
- The model or population studied.
- The measured endpoint and study duration.
What this evidence review covers
Explain why topical, laboratory, and injectable GHK-Cu cannot share one dosage chart.
- Route/formulation matrix
- Cell-culture concentration is not human dose
- Animal exposure is not a human conversion
- Injectable evidence gap
- No calculator
Source-backed findings
Each claim below is tied to the evidence class that can support it. Commercial listing data and clinical evidence remain separate.
preclinical
The cited biological findings come from cell or animal models, not a validated human dosage trial.
regulatory
FDA reports limited human safety data for injectable GHK-Cu.
| Evidence class | What the source supports |
|---|---|
| preclinical | The cited biological findings come from cell or animal models, not a validated human dosage trial. |
| regulatory | FDA reports limited human safety data for injectable GHK-Cu. |
Source-by-source evidence notes
These notes state what each inspected source can support and the boundary that should not be crossed when interpreting it.
GHK-Cu stimulation of collagen synthesis in fibroblast culture
Evidence class: primary in vitro. What it supports: Collagen synthesis under defined cell-culture conditions.
What it does not establish: Clinical skin, hair, wound, or injectable outcomes.
GHK-Cu connective-tissue accumulation in rat experimental wounds
Evidence class: primary animal. What it supports: Extracellular-matrix findings in a rat wound model.
What it does not establish: Human treatment outcomes or injectable dosing.
FDA bulk substances that may present significant safety risks
Evidence class: primary regulatory. What it supports: FDA's BPC-157, injectable GHK-Cu, and TB-500 fragment safety/characterization statements; no identified human TB-500 fragment exposure data.
What it does not establish: A diagnosis, individual risk estimate, or claim that topical GHK-Cu and injectable GHK-Cu share one risk profile.
Questions this page answers
What is the injectable GHK-Cu dose?
No validated human injectable schedule is established by this packet.
Can topical concentrations be converted to injections?
No. Routes, formulations, exposure, and safety evidence are not interchangeable.
What remains unresolved
- No route-matched randomized human dose-ranging evidence.
- No verified product equivalence.